Get the Stockscreener App
40.06
1.93%
-0.79
After Hours:
39.90
-0.16
-0.40%
Ionis Pharmaceuticals Inc stock is traded at $40.06, with a volume of 1.78M.
It is down -1.93% in the last 24 hours and down -15.98% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
See More
Previous Close:
$40.85
Open:
$40.76
24h Volume:
1.78M
Relative Volume:
1.14
Market Cap:
$6.32B
Revenue:
$813.46M
Net Income/Loss:
$-365.74M
P/E Ratio:
-13.96
EPS:
-2.87
Net Cash Flow:
$-375.18M
1W Performance:
-4.23%
1M Performance:
-15.98%
6M Performance:
-7.59%
1Y Performance:
-11.68%
1-Day Range:
$39.48
$40.88
1-Week Range:
$39.48
$41.85
52-Week Range:
$35.95
$54.44
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Transthyretin Amyloid Cardiomyopathy Market Size, Share, - openPR
Severe Hypertriglyceridemia Market Growth to Accelerate - openPR
Severe Hypertriglyceridemia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, 89bio, Inc., Arrowhead Pharma, Hightide Therapeutics, AstraZeneca, Kowa - Barchart
Ionis Pharmaceuticals Insiders Sold US$3.2m Of Shares Suggesting Hesitancy - Simply Wall St
Analysts Set Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target at $60.56 - MarketBeat
Bank of Montreal Can Has $10.52 Million Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Christie Ballantyne, MD: 'Exciting' Time for FCS Pipeline - MD Magazine
Susquehanna Portfolio Strategies LLC Sells 87,958 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Amyotrophic Lateral Sclerosis Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024 - The Globe and Mail
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Squarepoint Ops LLC - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat
Severe Hypertriglyceridemia Treatment Drugs, Pipeline Insights, Emerging Therapies and Companies 2024 - openPR
Transthyretin Amyloidosis Treatment Market Opportunities - openPR
Beta Thalassemia Pipeline 2024: Clinical Trials Assessment, - openPR
Ionis Pharmaceuticals GAAP EPS of -$1.03 in-line, revenue of $144M beats by $7.62M - MSN
Great Point Partners LLC Makes New $15.73 Million Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Renaissance Technologies LLC Raises Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
50,956 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Acquired by DRW Securities LLC - MarketBeat
State of New Jersey Common Pension Fund D Reduces Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Australia's Orica gains after positive H2 performance update - XM
ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Buy Rating from HC Wainwright - Defense World
Orica Updates Segments and Reports Solid Performance - TipRanks
Otis Worldwide Co. (NYSE:OTIS) Shares Sold by Wealthspire Advisors LLC - Defense World
Introducing Our Rant Against Ionis Pharmaceuticals Inc - US Post News
Nothing is Better Than Ionis Pharmaceuticals Inc (IONS) stock at the moment - SETE News
Examining OTIS’s book value per share for the latest quarter - US Post News
Investors in cash trouble should check out IO Biotech Inc (IOBT) - SETE News
IO Biotech (NASDAQ:IOBT) Rating Reiterated by HC Wainwright - Defense World
IO Biotech (NASDAQ:IOBT) PT Raised to $6.00 - Defense World
BMO Capital Markets analysts downgrades a Market perform rating for Ionis Pharmaceuticals Inc (IONS) - Knox Daily
IO Biotech Inc [IOBT] moved up 3.22: Why It’s Important - The DBT News
OSI Systems (NASDAQ:OSIS) Sees Unusually-High Trading Volume - MarketBeat
ORIX (NYSE:IX) Shares Gap Down to $122.44 - MarketBeat
Oric Pharmaceuticals, OpenBench launch discovery collaboration - TipRanks
OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration - PR Newswire
The ORIC Pharmaceuticals Inc (ORIC) had a good session last reading, didn’t it? - US Post News
In the Green: Ionis Pharmaceuticals Inc (IONS) Closes at 40.70, Up/Down -3.53 from Previous Day - The Dwinnex
Otis Worldwide Corp [OTIS] Investment Guide: What You Need to Know - Knox Daily
Ionos drops after Warburg Pincus places shares - XM
(OMI) Long Term Investment Analysis - Stock Traders Daily
Recent Insider Activity Suggests Potential Gains for Owens & Minor, Inc. (OMI) - Knox Daily
Otis Worldwide Corp. stock rises Monday, outperforms market - MarketWatch
Multiple System Atrophy Market on Track for Major Expansion - openPR
Analyzing IO Biotech Inc (IOBT) After Recent Trading Activity - Knox Daily
January 2027 Options Now Available For Ionis Pharmaceuticals (IONS) - Nasdaq
IOBT (IO Biotech Inc) has impressive results - US Post News
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study - Zacks Investment Research
Negative FDA AdCom vote on Ocaliva - The Pharma Letter
Analytical Overview: ORIC Pharmaceuticals Inc (ORIC)’s Ratios Tell a Financial Story - The Dwinnex
Market Momentum: IO Biotech Inc (IOBT) Registers a -2.20 Decrease, Closing at 0.75 - The Dwinnex
Principal Financial Group Inc. Sells 12,366 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):